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The recently cloned human interleukin  13 (IL-13) is a novel cytokine expressed in activated T 
cells that  has been shown to inhibit inflammatory cytokine production by lipopolysaccharide- 
activated monocytes. The protein encoded by the IL-13 cDNA is the human homologue of a 
mouse Th2-product called P600. Here, we show that IL-13 acts at different stages of the B cell 
maturation pathway: (a) it enhances the expression of CD23/FceRII and class II MHC antigens 
on resting  B ceils;  (b) it stimulates B cell proliferation in combination with  anti-Ig  and anti- 
CD40 antibodies; and (c) it induces IgE synthesis. Thus, the spectrum of the biological activities 
of IL-13 on B cells largely overlaps that previously ascribed to IL-4. The present observations 
suggest that IL-13 may be an important factor, in addition to IL-4, in the development of allergic 
diseases. 
T 
hl and Th2 T cell clones were first distinguished on the 
basis of their pattern of cytokine secretion (1, 2). Thl 
cells produce IL-2, IFN'y, and lymphotoxin,  whereas Th2 
cells produce IL-4, IL-5, IL-6, and IL-10 (3). It is now clear 
that these two Th cell subsets also display distinct functional 
capabilities. Thl cells play an important role in cell-mediated 
immunity and are good mediators of delayed-type hypersen- 
sitivity and cytotoxic T cell responses (3, 4). Conversely, Th2 
cells are particularly effective in providing help for humoral 
responses  (5). 
Human IL-13 has been recently cloned from a cDNA li- 
brary established from activated PBMC (6). IL-13 cDNA en- 
codes a polypeptide of 12.4 kD with four potential N-glyco- 
sylation sites presenting 60% amino acid homology with a 
previously cloned mouse Th2 T cell product known as P600 
(7, 8). No biological activity has been reported so far for P600, 
but human IL-13 shares with two other Th2-derived cytokines 
(IL-4 and IL-10) the capacity to inhibit  cytokine synthesis 
by activated monocytes (6, 9, 10). Due to the specific expres- 
sion of P600 by Th2  cells,  the human  counterpart  of this 
molecule could be considered  as a potential  modulator  of 
B cell responses.  Here, we report on the effects of recom- 
binant  human  IL-13  on  the  activation,  proliferation,  and 
differentiation  of human  B cells. 
tion of 1/600,  which provided the optimal  costimulatory  effect 
in proliferation assays. Formalinized particles of Staphylococcus aureus 
strain Cowan I (SAC)  1 were purchased as Pansorbin from Calbio- 
chem-Behring Corporation  (La JoUa, CA) and were used at a final 
concentration  of 0.005%  (vol/vol).  Recombinant  11.-2 (3  x  106 
U/rag) and purified recombinant IL-4 (2  x  107 U/mg) were pur- 
chased from Amgen Biologicals (Thousand  Oaks, CA).  Purified 
recombinant ILl0 was purchased from Immugenex (Los Angeles, 
CA) and was used at a final concentration of 100 ng/ml throughout 
the study. Recombinant  IL-13 was purified from culture superna- 
rants of stably transfected CHO cell lines, as described elsewhere 
(6). The anti-CD40  mAb G28-5 (11) was kindly provided by Dr. 
E. A. Clark (University of Washington, Seattle, WA) and was used 
at a final concentration  of 100 ng/ml. PE-conjugated anti-CD23 
mAb and FITC-conjugated monoclonals directed against HLA-DR., 
DP, DQ antigens were purchased from Becton Dickinson & Co. 
(Mountain View, CA). Culture supernatants of the OKT3 (CD3 
mAb) and OKTll (CD2 mAb) hybridoma cell lines were used for 
depletion of T cells from tonsils. The blocking rabbit anti-human 
Ib4 polyclonal antibody was purchased from Genzyme (Cambridge, 
MA) and was used at the final concentration  of 10/~g/ml.  The 
corresponding  negative control  was a preimmune  rabbit  serum. 
The mouse Ltk-  cell line D1B1 (12), stably expressing the mu- 
rine IgG Fc receptor (Fc3'RII) was kindly provided by Dr. C. Sautes 
(INSERM U. 255, Institut Curie,  Paris, France). 
B Cell Preparations.  B cells were isolated from tonsils as previ- 
Materials and Methods 
Reagents and Cytokines.  Rabbit anti-human  Igs (heavy and light 
chains) coupled to polyacrylamide beads were purchased from Bio- 
Rad Laboratories (Richmond,  CA) and were used at a final dilu- 
1 Abbreviations used in this paper: B-CLL, chronic lymphocytic leukemia 
B cells; GC, germinal center; MFI, mean fluorescence  intensity; PBA, 
polyclonal B cell activator; SAC, Staphylococcus aureus strain Cowan I. 
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blood cells,  nonrosetting cells were further incubated with anti- 
CD2 and anti-CD3 mAbs before negative selection performed with 
magnetic beads coated with anti-mouse IgG (Dynabeads; Dynal, 
Oslo, Norway). The purity of the B cell populations obtained by 
this procedure was routinely superior to 98% as estimated by flow 
cytometry analysis  using anti-CD19,  -CD20,  -CD2,  -CD3,  and 
-CD14 mAbs. slgD + and slgD- B cells were isolated  as described 
previously (13) using a preparative magnetic cell separation system 
(MACS|  Becton Dickinson & Co.).  The purity of both B cell 
populations  was routinely superior to 95%. 
Leukemic B cells were obtained from a patient with hematolog- 
ically diagnosed chronic lymphocytic leukemia. B cells were iso- 
lated from peripheral blood, according to the procedure described 
above,  and contained more than 95% leukemic cells as estimated 
by the expression of the CD5 antigen, which is constitutively ex- 
pressed on chronic lymphocytic leukemia B cells  (B-CLL). 
Cultures.  All cultures were performed in RPMI 1640 supple- 
mented with 10% selected heat-inactivated  FCS, 2 mM L-glutamine, 
100 U/ml penicillin,  100 #g/ml streptomycin, and 2% Hepes (all 
from Gibco Laboratories, Grand Island, NY). For CD23 and class 
II MHC antigen induction experiments, B cells (106/ml) were cul- 
tured for 48 h in the absence of stimulating agent, or in the pres- 
ence of IL-4 or IL-13 used at 100 ng/ml. At the end of the culture 
period, cells were stained with PE-conjugated anti-CD23 or FITC- 
conjugated anti-HLA-DR, DP, or DQ monoclonals and analyzed 
on a FACScan |  using the Lysis software. (Becton Dickinson & Co.) 
Propidium iodide (2 #g/ml) was added to each sample (except when 
staining was performed with PE-conjugated antibodies)  before flow 
cytometry analysis  to gate out nonviable cells.  For proliferation 
assays, B cells were seeded  at 1.5  x  105 cells/well in 96-well  mi- 
crotiter trays in a final volume of 0.1 ml. Cytokines and polyclonal 
B cell activators (anti-Ig or anti-CD40 antibodies) were added at 
the onset of the culture. Each culture point was performed in tripli- 
cate. At the times specified in the text, DNA synthesis was deter- 
mined by pulsing the cells with [3H]thymidine ([3HITdR)  for the 
last 16 h of the culture period. For differentiation assays performed 
with polyclonal B cell activators (SAC  and anti-CD40 mAb), B 
cells were seeded  at 3  x  1@ cells per well in 96-well  microtiter 
trays,  in a final culture volume of 0.25 ml. When SAC was used 
as the stimulating agent, the addition of cytokines was made ei- 
ther at the onset of the culture (costimulation assay) or was delayed 
for 2 d (restimulation assay). For assays aimed at determining the 
influence of IL-13 on IgE synthesis, two distinct activation systems 
were used. In the first one, B cells were co-cultured with mitomycin- 
treated  (75  #g/ml,  45  rain,  370C)  T  cells  activated by phyto- 
hemagglutinin-P (PHA; Difco Laboratories, Inc., Detroit, MI). In 
these experiments, 3  x  1@ T cells, purified from peripheral blood 
by filtration on nylon wool columns, were added together with 
cytokines and PHA (1/~g/ml) to 5  x  10  s B cells, in 24-well plates, 
in a final volume of 1 ml. In the second one, purified B cells were 
activated by the anti-CD40 mAb G28-5 presented by the D1B1 
cell line, stably expressing the murine FcTRII. In these experiments, 
5  x  10  s B cells were co-cultured in 24-well plates with 2  x  105 
irradiated (7,000 rad) DIB1 cells and the G28-5 mAb (100 ng/ml) 
in the presence of IL4 (200 ng/ml) or IL-13 (100 ng/ml), with or 
without addition of anti-IL4 or control antisera (10 #g/ml). Each 
culture point was performed in six replicates (T/B cell co-cultures) 
or in quadruplicates (co-cultures with DIB1 cells). For determina- 
tion ofimmunoglobulin production, culture supernatants were har- 
vested at day 10 and IgM, IgG, IgA, and IgE levels were measured 
in  standard ELISAs (14, 15). 
Results 
IL-13 Enhances Expression of CD23 and Class II MHC An- 
tigens on B  Cells.  To examine the capacity of IL-13 to exert 
an influence on the early B  cell activation  steps, both ton- 
sillar B cells and leukemic B cells from a B-CLL patient were 
assessed for CD23  expression after a 48-h culture period in 
the presence of 100 ng/ml purified recombinant IL-13 or IL-4. 
The results from one representative experiment are illustrated 
by Fig.  1. As described earlier (16,  17), CD23 was constitu- 
tively expressed on the leukemic clone (Fig.  1 E),  whereas 
it was only distributed  on a subset of normal B  cells (Fig. 
1 A).  In agreement with previously published reports (17), 
normal and leukemic B  cells (Fig.  1, B  and F,  respectively) 
almost totally lost the  expression of CD23,  in  the absence 
of stimulant.  Both IL-13 (Fig.  1,  C  and G) and IL-4 (Fig. 
1, D  and H) were able to induce reexpression  of CD23  on 
leukemic  and  normal  B  cells.  However,  the  proportion  of 
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Figure  1.  Expression  of CD23 on normal 
and leukemic  B cells cultured with Ib13 or IL-4. 
Purified tonsillar B cells (A-D) or B-CLL cells 
(E-H) were cultured for 48 h with purified 
recombinant IL-13 (100 ng/ml; C and G) or 
with purified recombinant IL-4 (100 ng/ml; D 
and H). A control, in which B cells were cul- 
tured in the absence  of stimulant (/7 and F) was 
also included in the experiment. The constitu- 
tive expression of CD23 on freshly  isolated ton- 
sillar B cells and B-CLL cells is shown in A 
and E, respectively.  The fluorescence  histograms 
obtained after staining with the PE-conjugated 
anti-CD23 mAb (plain lines) were superimposed 
with the negative control performed with an 
isotype-matched unrelated mAb (dashed  lines). 
The proportion  of CD23-expressing cells as 
well as the mean fluorescence intensity of the 
fluorescence histogram (in parentheses) are in- 
dicated below the FACS  |  profiles. Fluorescence 
is expressed on a logarithmic scale. The figure 
is representative of three separate experiments. 
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class II MHC antigen expression on leukemic 
B cells. B-CLL cells were cultured for 48 h in 
the presence  of Ib13 at 100 ng/ml (plain lines) 
or in the absence of any stimulant (dashed lines), 
and analyzed  by flow cytometry after staining 
with  FITC-conjugated anti-HLA-DR,  DP, 
and DQ monoclonals. The negative control 
performed with an isotype-matched  unrelated 
mAb is also shown (first plain line histogram on 
the left of each panel). Data are shown on a log- 
arithmic scale. The MFI values of the fluores- 
cence histograms for DR, DP, and DQ were 
560, 272, and 171, respectively, for cultures 
stimulated with IL-13, vs. 181, 44, and 38 for 
untreated cultures. The figure is representative 
of three experiments. 
CD23-positive cells as well as the density of CD23 antigens 
per cell, estimated by the mean fluorescence intensity (MFI) 
of the fluorescence histogram, were consistently lower in cul- 
tures stimulated with IL-13 than in cultures stimulated with 
IL-4. The half-maximal effect of IL-13 on CD23 induction, 
estimated on normal tonsillar B cells, was reached with con- 
centrations of IL-13 on the order of 3 ng/ml (data not shown). 
In contrast with IL-4, IL-13 totally failed to enhance CD23 
expression on the Burkitt lymphoma cell line Jijoye (data not 
shown).  As  illustrated  by  Fig.  2,  IL-13  was  also  able  to 
significantly increase expression of the HLA-DR,  DP,  and 
DQ antigens on B-CLL cells. At optimal concentrations of 
both cytokines,  the signal  provided by IL-13 for enhance- 
ment of class II MHC antigens was of similar amplitude to 
that provided by IL-4 (data not shown),  and up to sixfold 
increases in MFI were observed for HLA-DP antigens in re- 
sponse  to IL-13. 
IL-13 Stimulates Growth of Activated B Cells.  Purified recom- 
binant IL-13 and IL-4 were next compared for their capacity 
to stimulate DNA synthesis from human tonsillar B cells ac- 
tivated either through cross-linking of surface Igs using im- 
mobilized anti-Ig antibodies or through ligation of CD40 
antigens  using  the  anti-CD40  mAb  G28-5.  As  shown  in 
Fig. 3, IL-13 enhanced [3H]TdR incorporation of activated 
human B lymphocytes, in a dose-dependent fashion, in both 
culture systems, a plateau being reached at 50 ng/ml. As ob- 
served for CD23 induction, the half-maximal effect of IL-13 
on B cell proliferation was obtained for a concentration of 
~3  ng/ml.  On  average,  at  optimal  concentration  of both 
cytokines, the levels of [3H]TdR incorporation induced by 
IL-13 were approximately two times lower than  those in- 
duced by IL-4, regardless of the activating stimulus applied. 
No stimulation of B cell growth was observed when IL-13 
was tested in the absence of costimulating  agent (data not 
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Figure 3.  Titration of the growth-promoting 
activity of II.-13 on B cells activated through slgs 
or CD40. 1.5  x  10  s B cells were cultured with 
serial dilutions of purified recombinant IL-13 or 
purified recombinant IL-4, in combination with 
immobilized anti-Ig antibodies (1/600 dilution) or 
with the anti-CD40 mAb G28-5 (100 ng/ml). 
[3H]TdR incorporation levels were assessed at day 
3, after a 16-h pulse. The mean +_ SD rates of in- 
corporation from triplicate wells of a typical ex- 
periment are shown. The figure is representative 
of three separate experiments. 
137  Defiance  et al. shown).  To  examine  whether  IL-13  could  modulate  the 
growth-promoting effect of other B cell stimulatory cytokines, 
anti-Ig or anti-CD40-activated B cells were cultured with 
optimal concentrations of IL-2 (20 U/ml), IL-4 (200 ng/ml), 
or IL-10 (100 ng/ml) in the presence or absence of an op- 
timal concentration of IL-13 (100 ng/ml).  As indicated by 
the data summarized in Table 1, IL-2 and IL-10, but not IL-4, 
were able to cooperate with IL-13 to induce proliferation of 
activated B cells. As expected from previous results (18), IL-2 
failed to stimulate DNA synthesis from anti-CD40-activated 
B cells, whereas IL-10 was virtually inactive on anti-Ig-acti- 
vated B  cells.  Accordingly, enhancement by IL-13 of the 
growth-promoting effects of IL-2 and IL-10, was observed 
in the anti-Ig and anti-CD40 activation systems, respectively. 
As demonstrated by kinetics studies (Fig. 4), cooperation be- 
tween IL-13 and IL-2 or between IL-13 and IL-10, for B cell 
growth, was observed throughout the culture period, with 
the exception of the earlier time point. At the peak of the 
proliferative response (day 2 for anti-Ig-activated B cell, day 
3 for anti-CD40-activated B cells), the levels of stimulation 
reached with IL-13 +  IL-2 or IL-13  +  IL-IO, were approxi- 
mately equivalent to the sum of the responses elicited by each 
factor alone. 
Tonsil B cells can be separated into two major B cell popu- 
lations, on the basis of surface IgD expression (13).  slgD + 
B cells are representative of virgin B  cells of the follicular 
mantle, whereas slgD- B cells include germinal center (GC) 
B cells as well as extra-follicular B cells.  Thus, slgD + and 
slgD- B cells were compared for their ability to respond by 
DNA synthesis to IL-13 used in combination with immobi- 
lized anti-Ig antibodies or with the anti-CD40 mAb G28-5. 
Table  1.  Interplay  of lL-I3 and Other Cytokines on B Cell Growth 
[3H]Thymidine incorporation 
Cytokines  IL-13  Anti-Ig  Anti-CD40 
cpm  x  10 -~ 
-  -  4.7  12.2 
-  +  33.9  21.9 
IL-2  -  33.3  14.0 
IL-2  +  65.3  25.2 
IL-4  -  84.3  45.6 
IL-4  +  84.6  42.7 
IL-10  -  4.8  33.4 
IL-10  +  25.8  48.6 
Purified B cells were seeded  at 1.5  x  105 cells/well, in microtiter  trays, 
and stimulated  with immobilized  antiqg antibodies or with the antbCD40 
mAb G28-5 in the absence or presence  of IL-2 (10 U/ml) or IL-IO (100 
ng/ml), used either alone or in combination with IL-13 (100 ng/ml). 
Cultures were terminated at 72 h after a 1-#Ci [3HITdR pulse for the 
final 16 h. Results are expressed as mean of triplicate determinations. 
SD never exceeded  10% of the mean values. The table is representative 
of three separate experiments. 
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Figure 4.  Effect  of combinations of IL-13 and IL-2 or IL- 13 and IL-10 
on the proliferative  response  of activated B cells. 1.5  x  10  s B cells were 
cultured with Ib13 (100 ng/ml), Ib2 (10 U/ml), I1.-13 +  IL-2, in the 
presence of immobilized  antiqg antibodies (1/600 dilution); or with IL- 
13, Ibl0 (100 ng/ml), IL-13 + IL-10, in the presence of the anti-CD40 
mAb G28-5 (100 ng/ml). Cells were pulsed with [3H]TdR at the indi- 
cated times, cultures being terminated 16 h later. Results correspond  to 
the mean _+ SD values of three separate experiments. 
As a control, the influence of IL-2 and anti-Ig antibodies on 
the growth response of  both populations was also examined. 
As shown in Fig.  5,  slgD + B cells displayed  an enhanced 
responsiveness to the growth stimulatory effect of IL-13, when 
compared with slgD- B cells, in both the antiqg and anti- 
CD40 activation systems.  The levels of DNA synthesis in- 
duced by IL-13 in the former population were, on average, 
two to five times superior to those induced in the latter. In 
contrast, the proliferative response of slgD-  B cells to the 
combination of IL-2 and immobilized anti-Ig antibodies was 
markedly higher  than  that  of slgD +  B  cells,  at  all  time 
points. This observation therefore rules out the possibility 
of an impaired responsiveness  of slgD-/3 cells to mitogenic 
stimuli.  Taken together, these findings indicate that IL-13 
is a B cell growth-factor whose preferential cellular target 
is virgin slgD + B cells. 
IL-13 Induces IgE Synthesis.  We next examined the activity 
of IL-13 on B cell differentiation. IL-13 was first compared 
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B cell populations are indicated for each culture condition.  B cells were cultured at  the cell density of 1.5 
Figure  5.  Response of sIgD § 
and slgD- B cells to the growth- 
stimulatory effect of IL-13. Purified 
slgD + (closed symbols) and slgD- 
B cells (open symbols) isolated from 
tonsils were costimulated with: (a) 
IL-13 (100 ng/ml) and immobilized 
anti-Ig antibodies (1/600 dilution, 
A);  (b) II.-13 and the anti-CD40 
mAb G28-5 (100 ng/ml; B); and (c) 
IL-2 (10 U/ml)  and immobilized 
anti-Ig antibodies (C). The levels of 
stimulation  induced by  the  ac- 
tivating agent alone (PBA) in both 
x  105 cells per well in  96  well- 
microtiter trays. Cells were pulsed with [3H]TdR at the indicated times, cultures being terminated 16 h later. Results correspond to the mean +  SD 
values of triplicate determinations. The figure is representative of three separate experiments. -4~,  slgD */PBA; -I1-, slgD +/PBA  +  cytokine; 
-O-, slgD-/PBA; --[~--, slgD-/PBA  +  cytokine. 
with IL-2 for its capacity to induce polyclonal Ig secretion 
from activated B cells,  in four distinct assay systems: (a) co- 
culture with SAC; (b) co-cuhure with the anti-CD40 mAb 
G28-5; (c) co-culture with SAC and anti-CD40; (d) restimu- 
lation of B cells preactivated with  SAC for 2 d.  The latter 
culture condition was included in our study in order to avoid 
underestimation of the Ig-inducing activity of IL-13 due to 
its presence during the initial activation with SAC. Indeed, 
the development of the stimulatory effect of IL-4 on B cell 
differentiation had been shown to be prevented when SAC 
and IL-4 were added simultaneously on B cells (19). As shown 
in Table 2, IL-13 failed to stimulate IgM, IgG, and IgA syn- 
thesis,  whatever the mode of B cell activation used.  How- 
ever, a low but reproducible IgE response was observed when 
B cells were co-cultured with IL-13 and soluble anti-CD40 
antibodies.  In spite of its capacity to enhance the prolifera- 
tive response induced by IL-2 and IL-10, IL-13 did not affect 
the IgM, [gG, and IgA synthesis elicited by these two cytokines 
in the SAC restimulation assay (Fig. 6) or in the three other 
culture systems described above (data not shown). IL-13 also 
Table  2.  Effect of lL-13  on Ig Secretion by Human B  Cells Activated  by SAC or Soluble Anti-CD40 Antibodies 
Immunoglobulin production 
Activators  Cytokines  IgM  IgG  IgA  IgE 
SAC (costimulation) 
Anti-CD40 
SAC  +  anti-CD40 
SAC (restimulation) 
r  ~g/ml  /.tg/ml  pg/ml 
none  0.3  0.1  0.05  <156 
IL-13  0.6  0.1  0.05  <156 
IL-2  5.0  14.8  0.8  <156 
none  0.2  0.2  0.05  <156 
IL-13  0.4  0.3  0.06  300 
IL-2  0.5  1.0  0.3  <156 
none  0.8  0.4  0.05  <156 
IL-13  1.3  0.4  0.1  <156 
IL-2  5.9  13.0  1.0  <156 
none  0.3  0.1  0.03  <156 
IL-13  0.5  0.1  0.05  <156 
IL-2  3.6  10.9  0.2  <  156 
Purified B ceils were seeded at 3  x  10  s cells/well and activated by SAC (0.005%, vol/vol), by the anti-CD40 mAb G28-5 (100 ng/ml) or by the 
combination of SAC and anti-CD40 in the presence or absence of optimal concentrations of IL-13 (100 ng/ml) or IL-2 (10 U/ml). When SAC 
was used as the stimulating agent, cytokines were either added together with  SAC at the onset of the culture (costimulation assay) or 2 d after 
establishment of the culture (restimulation assay). Supernatants were harvested at day 10 and Ig levels were determined by ELISA. Results are means 
of quadruplicate determinations. SD never exceeded 10% of the mean values. IgM, IgG, and IgA levels are expressed in/xg/ml, IgE levels are ex- 
pressed in pg/ml. This table is representative of four separate experiments. 
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Figure  6.  Influence  of IL-13 on the IgM, IgG, and IgA response  elicited 
by B cell stimulator)' cytokines. B cells were dispensed in microtiter trays 
at the density of 3  x  10  s cells per well, together with SAC (0.005%, 
vol/vol), under a final culture volume of 0.25 ml. IL-2 (10 U/ml), I1+-4 
(100 ng/ml), and ILl0 (100 ng/ml) were added alone or in the presence 
of Ib13 (100 ng/ml) on the second day of the culture. Ig levels  were tested 
in 10-d culture supernatants by specific  ELISAs. Results are expressed in 
/zg/ml and correspond to the mean _+ SD values calculated on eight cul- 
ture replicates, m,  -IL13;  D,  +IL-13. 
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failed to modulate the IL-4-mediated secretion of these iso- 
types. Since signals provided by activated T  cells have been 
described to be instrumental  for induction of IgE synthesis 
in response to IL-4 (20, 21), IL-13 was first tested for its IgE- 
inducing capacity in cultures in which B cells were activated 
by mitomycin-treated  T  cells,  in  the  presence  of PHA  (1 
/zg/ml). Because activated T cells have been shown to induce 
B cells for DNA synthesis and Ig secretion in a class II unre- 
stricted and nonantigen-specific fashion (22), T cells used for 
T/B  cell co-cultures  were isolated  from peripheral  blood, 
whereas B cells were purified from tonsils. The T/B cell ratio 
in these experiments was 6/1.  As shown in Table 3, IL-13 
did not significantly enhance the production of IgM,  IgG, 
and IgA but markedly increased the IgE synthesis induced 
by activated T  cells. To rule out the possibility that part or 
all of the IgE-inducing  activity of IL-13 could be mediated 
through the endogenous release of IL-4, IL-13 was also tested 
for its capacity to induce IgE synthesis in a culture system 
devoid of potential IL-4-producing cells. Regarding that IL-4 
can efficiently stimulate B cells for IgE secretion when they 
are activated by anti-CD40 antibodies presented by a mouse 
fibroblastic cell line transfected with the human IgG Fc receptor 
(23), we decided to assess the IgE-stimulatory effect of IL-13 
in a similar  experimental  model.  For this purpose,  B cells 
were co-cultured with the anti-CD40 mAb G28-5, presented 
by the D1B1 cell line stably expressing the murine Fc3,RII, 
and  IL-4 or IL-13,  in  the presence  or absence of a rabbit 
anti-human IL-4 polyclonal antibody. As shown in Table 4, 
IL-4 and IL-13, both used at optimal concentrations, induced 
equivalent levels of IgE synthesis from B cells activated by 
immobilized anti-CD40 antibodies. IL-13 failed to stimulate 
any IgM or IgA production in that culture system, but mar- 
ginal enhancements (two times the background levels) of IgG 
secretion were observed (data not shown). Neutralizing poly- 
clonal anti-IL-4  antibodies,  but not  the preimmune  rabbit 
serum, completely blocked the IgE-inducing activity of IL-4. 
In contrast, the anti-IL-4-neutralizing  antiserum did not an- 
tagonize the IgE-stimulatory effect of IL-13. Taken together 
these results indicate that IL-13 stimulates IgE secretion in 
an  IL-4-independent  fashion. 
Discussion 
In the present report, we have demonstrated that human 
IL-13 is susceptible to act on three distinct  stages of the B 
cell maturation process: (a) during the early activation phase, 
by enhancing expression of CD23 and of class II MHC an- 
tigens on resting B cells;  (b) during the proliferation phase, 
by stimulating  growth  of activated B cells;  (c) during  the 
differentiation phase,  by inducing IgE synthesis.  Thus,  the 
spectrum of biological activities of IL-13 on human B cells 
presents striking similarities with that previously ascribed to 
IL-4 (24), although the IL-13-mediated responses were gener- 
ally of lower amplitude than those elicited by IL-4. For ex- 
ample, the levels of CD23 expressed on IL-13-stimulated B 
cells,  after 48 h  of culture,  were approximately equivalent 
to those found on freshly isolated B cells. In contrast,  IL-4 
not only induced higher levels of CD23 expression but also 
recruited a larger proportion of tonsillar B cells to become 
CD23-positive. In view of the fact that CD23 rapidly disap- 
pears from the B cell membrane in the absence of stimulant 
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IgM  IgG  IgA  IgE 
ltg/ml  l~g/ml  /tg/ml  ng/ml 
B  0.4  +  0.01  0.3  _+  0.01  0.3  +_ 0.04  <0.1 
B  +  T  26  +  0.4  12.7  +  0.2  2.1  _+ 0.1  2.6  +  0.1 
B  +  T  +  IL-13  28  +_ 0.7  9.8  _+ 0.3  1.7  +_ 0.07  11.8  +  0.9 
B  +  T  +  IL-4  35  _+  1.6  10.9  _+  0.6  2.2  _+ 0.1  20.9  _+  1.2 
Purified tonsillar B cells (5  x  10S/well) were co-cultured for 10 d with mitomycin-treated peripheral blood T cells (3  x  106/well) and PHA (1 
/xg/ml) in the absence or in the presence of IL-4 (100 ng/ml) or IL-13 (100 ng/ml).  Each culture point was performed in six replicates in 24-well 
plates under a final culture volume of 1.0 ml. Supernatants from the culture replicates were pooled and Ig levels were determined by ELISA. Results 
are expressed  as means •  SD of quadruplicate ELISA determinations. IgM, IgG, and IgA levels are expressed  in/~g/ml, IgE levels are expressed  in ng/ml. 
(17), it can not be excluded that IL-13 acts by stabilizing the 
CD23 molecule on the cell surface (for example by preventing 
the proteolytic cleavage or shedding of its soluble form) rather 
than by activating  the CD23  gene. 
As observed for CD23 induction, the growth-stimulatory 
effect of IL-13 on B cells activated either through cross-linking 
of slgs or ligation of CD40 was less pronounced than that 
of IL-4. Examination of the B cell proliferative response to 
IL-13  used  in  combination  with  other  B  cell-stimulatory 
cytokines revealed one point of discrepancy between IL-4 and 
IL-13. Indeed, although IL-4 and IL-13 shared the capacity 
to enhance the growth-response induced by IL-10 (25), IL-13 
potentiated the DNA synthesis elicited by IL-2, whereas there 
is published evidence that IL-4 antagonizes the human B cell 
Table  4.  The IL-13-mediated Induction of IgE Synthesis Is 
IL-4  Independent 
IgE secretion 
+  control 
Med*  +  anti-IL-4  antiserum 
ng/ml 
Med  <0.15  ND  ND 
IL-4  11  _+  0.7  <0.15  8.5  --  0.4 
IL-13  12  _+  0.8  11  _+  0.4  9  _+ 0.3 
Purified tonsillar B cells (5  x  10S/well)  were activated  by the anti-CD40 
mAb G28-5 (100 ng/ml) presented by the irradiated fibroblast cell line 
DIB1  stably expressing the  murine  Fc~/RII (2  x  10S/well). Anti- 
CD40-activated B cells were cultured with purified recombinant IL-4 
(100 U/ml) or IL-13 (100 ng/ml) in the presence or absence of: (a) a 
rabbit anti-human  IL-4 polyclonal antibody (10/~g/ml);  (b) a control 
rabbit anti-serum (10/~g/ml). Each culture point was performed in qua- 
druplicates in 24-well plates. Supernatants from the culture replicates har- 
vested on day 10 were pooled and IgE concentrations were measured by 
ELISA. Results are expressed as means _+ SD of quadruplicate ELISA 
determinations. IgE levels are expressed in ng/ml. 
*Med, Medium. 
responses to this cytokine (26, 27). We suspect that the posi- 
tive interplay between IL-2 and IL-13 on B cell proliferation 
could relate to the fact that the two molecules have distinct 
cellular  targets.  IL-13  predominantly  induced  growth  of 
slgD + B cells, whereas, in accordance with a previous pub- 
lished  report  (28),  IL-2  had  a  preferential  impact  on  the 
slgD-  subset which is enriched for GC-derived B cells. This 
finding is consistent with the hypothesis that a larger B cell 
population is recruited to proliferate when IL-2 and IL-13 
are combined, than when each cytokine is used alone. Addi- 
tionally, the enhanced responsiveness of virgin slgD + B cells 
to IL-13 raises the possibility that this cytokine could be in- 
volved in the establishment of the primary humoral response 
rather than in the development of the secondary immune re- 
sponse. 
Despite  the fact that  IL-13 behaved as a B  cell growth- 
factor, it was virtually unable to induce IgM, IgG, and IgA 
synthesis from activated B cells in different assay systems, thus 
implying that IL-13 does not play a major role in the regula- 
tion of the production of these Ig isotypes. However, IL-13 
selectively stimulated IgE secretion from B cells co-cultured 
with activated T cells or with an anti-CD40 mAb presented 
by a fibroblastic cell line expressing the murine Fc~/RII. The 
observation that neutralizing  anti-IL-4 antibodies failed to 
antagonize the IgE-stimulatory effect of IL-13, in a T cell-free 
culture system demonstrates that IL-13 operates through an 
IL-4-independent mechanism. Since the biological effects of 
IL-13 are preferentially directed at slgD + B cells it is likely 
that the IgE-inducing activity of IL-13 results from isotype 
switching rather than from differentiation of IgE-committed 
precursors. 
Based on the observation that IL-4 and IL-13 have a highly 
overlapping set of biological activities on human B cells, it 
is  tempting  to  speculate that  these  two cytokines,  despite 
limited protein sequence homology, could share receptor sig- 
naling pathways.  Experimental evidence has been provided 
that this is the case for other cytokines such as IL-5, IL-3, 
and GM-CSF which share a common receptor suhunit respon- 
sible for signal  transduction  (29).  Until  recently, the IL-4 
receptor was believed to consist of a single chain binding IL-4 
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when transfected in various cell lines (24, 29). However, two 
lines  of evidence now  support  the existence  of two IL-4 
receptors of different affinities, possibly coupled to separate 
signal transduction pathways. First, Rigley et al., (30) have 
shown that the IL-4-mediated enhancements of sIgM and 
CD23 expression on human B cells are regulated indepen- 
dently through distinct second messenger cascades. Second, 
an additional IL-4 binding protein of low affinity  has recently 
been identified on human pre-B cells (31). Thus, the possi- 
bility exists of a multisubunit IL-4 receptor including poten- 
tial IL-13 signal transducing molecules. It can not be excluded 
that the IL-13 receptor may also be coupled to a unique sig- 
naling pathway, as suggested by the observation that IL-4 
and  IL-13  display  opposite  effects  on  the  IL-2-mediated 
proliferation of activated B cells. 
Although IL-13 would appear to contribute an additional 
redundancy in the cytokine regulation of the B cell matura- 
tion process it may be unique in its capacity to preferentially 
induce growth of virgin slgD + B cells. It does not signifi- 
cantly affect the production of the IgM, IgG, and IgA iso- 
types but stimulates IgE synthesis and as such might con- 
tribute to the development of allergic  diseases. In keeping 
with this, although IL-4 has been implicated by gene-deletion 
experiments (32, 33) as the major, if not the unique switch 
factor for IgE in the mouse, the existence  of an additional 
IgE-inducing activity, produced by T  cells from atopic pa- 
tients, has been recently demonstrated (34).  This observa- 
tion raises the possibility that an IL-4-independent mecha- 
nism of IgE regulation, possibly mediated by IL-13 might 
operate in atopic individuals. 
We would like to thank Dr. D. Kaiserlian and Dr. R. Buckland (Institut  Pasteur de Lyon) for critical 
review of the manuscript. We gratefully acknowledge the expert editorial assistance of B. Maret. 
Address correspondence to T. Defiance, Unite D'Immunologie et Strategie Vaccinale, Institut Pasteur 
de Lyon, Avenue Tony Garnier, 69365 Lyon Cedex 07, France. 
Received for publication 22 April 1993 and in revised form  18 August  1993. 
References 
1.  Kim, J., A. Woods, E. Becker-Dunn, and K. Bottomly. 1985. 
Distinct functional phenotypes of cloned Ia-restricted helper 
T cells.  J. Exp. Med. 162:188. 
2.  Mosmann, T.R., H. Cherwinski, M.W. Bond, M.A. Giedlin, 
and R.L. Coffman. 1986. Two types of murine helper T cell 
clone. I. Definition according to profiles of lymphokine ac- 
tivities and secreted proteins, j. Immunol. 136:2348. 
3.  Mosmann, T.R., J.H. Schumacher, N.F. Street, R. Budd, A. 
O'Garra, T.A.T. Fong, M.W. Bond, K.W.M. Moore, A. Sher, 
and D.F. Fiorentino. 1991. Diversity ofcytokine synthesis and 
function of mouse CD4 + T cells. Immunol. Rev. 123:209. 
4.  Cher, D.J., and T.R. Mosmann. 1987. Two types of murine 
helper T cell clone. II. Delayed-type hypersensitivity is medi- 
ated by Thl clones. J. Immunol. 138:3688. 
5.  Sanders, V.M., and E.S. Vitetta. 1990. Collaboration between 
T and B cells. In Cytokines and B Lymphocytes.  R.E. Callard, 
editor. Academic Press, London. 173-193. 
6.  Minty,  A.,  P.  Chalon,  J.-M.  Derocq,  X.  Dumont, J.-C. 
Guillemot, M. Kaghad, C. Labit, P. Leplatois, P. Liauzun, B. 
Miloux, et al. 1992. Interleukin-13  is a new human lymphokine 
regulating inflammatory  and immune responses. Nature (Lond.). 
362:248. 
7.  Cherwinski, H.M., J.H. Schumacher, K.D. Brown, and T.R. 
Mosmann. 1987. Two types of mouse helper T ceU clone. III. 
Further differences  in lymphokine synthesis between Thl and 
Th2 clones revealed  by RNA hybridization,  functionally  mono- 
specific bioassays, and monoclonal antibodies. J. Extx  Med. 
166:1229. 
8.  Brown, K.D., S.M. Zurawski, T.R. Mosmann, and G. Zuraw- 
ski. 1989. A family of small inducible proteins secreted by leu- 
cocytes are members of a new superfamily  that includes leuco- 
cyte and fibroblast-derived  inflammatory  agents, growth factors, 
and indicators of various activation processes, j.  Immunol. 
142:679. 
9.  te Velde, A.A., K.J.F. Huijbens, K. Heije, J.E. de Vries, and 
C.G. Figdor. 1990. Interleukin 4 (II.-4) inhibits secretion of 
IL-13, tumor necrosis factor-a, and IL-6  by human monocytes. 
Blood. 76:1392. 
10.  de Waal Malefyt, R., J. Abrams, B. Bennett, C.G. Figdor, and 
J.E. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine syn- 
thesis by human monocytes: an autoregulatory role of IL-IO 
produced by monocytes, j. Exp. Med. 174:1209. 
11.  Clark, E.A., and J.A. Ledbetter. 1986. Activation of human 
B cells mediated through two distinct cell surface differentia- 
tion antigens, Bp 35 and Bp 50. Proc. Natl. Acad, Sci. USA. 
83:4494. 
12.  Sautes, C., N. Varin, C. TeiUaud, M. DaCron,  J. Even, RM. 
Hogarth, and W.H. Fridman. 1991. Soluble Fc  3, receptors II 
(Fc3~RII) are generated by cleavage  of  membrane FcyRII. Eur. 
J. Immunol. 21:231. 
13.  Defiance, T., B. Vanbervliet, F. Bri~re, I. Durand, F. Rousset, 
and J.  Banchereau. 1992. Interleukin  10 and transforming 
growth factor  ~ cooperate to induce anti-CD40-activated  naive 
human B cells to  secrete immunoglobulin A.J.  Exp. Med. 
175:671. 
14.  Defiance, T., B. Vanbervliet,  J. P~ne, andJ. Banchereau. 1988. 
Human recombinant IL-4 induces activated B lymphocytes to 
produce IgG and IgM. J. ImmunoI. 141:2000. 
15.  Chr~tien, I., J. P~ne, F. Bri~re, R. de Waal  Malefyt, E Rousset, 
and J.E. de Vries. 1990. Regulation of IgE synthesis: human 
142  B Cell Stimulator),  Activities of Human II.-13 IgE  synthesis in  vitro is  determined by the  reciprocal  an- 
tagonistic effects of IL-4 and IL-3'. Eur. j. Immunol. 20:243. 
16.  Defiance,  T., J.P.  Aubry,  F.  Rousset,  B.  Vanbervliet,  J.Y. 
Bonnefoy, N. Arai, Y. Takebe, T. Yokota, F. Lee, K. Arai, et 
al.  1987.  Human  recombinant  interleukin  4  induces  Fce 
receptors (CD23) on normal human B lymphocytes. J. Exp. 
Med. 165:1459. 
17.  Delespesse, G., M. Sarfati, C.Y. Wu, S. Fournier, and M. Letel- 
lier.  1992.  The low-affinity receptor for IgE. Immunol. Rev. 
125:78. 
18.  Defrance, T., B. Vanbervliet,  I. Durand, J. Briolay, andJ. Ban- 
chereau.  1992.  Proliferation  and  differentiation  of human 
CD5 § and CD5-  B cell subsets  activated through their an- 
tigen receptors or CD40 antigens. Eur. j. Immunol. 22:2831. 
19. Jelinek, D.F., and P.E. Lipsky.  1988. Inhibitory influence of 
IL-4 on human B cell responsiveness. J. Immunol. 141:164. 
20.  Vercelli, D., H.H. Jabara, K.-I. Arai, and R.S. Geha. 1989. 
Induction of human IgE synthesis  requires interleukin 4 and 
T/B cell interactions involving the T cell receptor/CD3 com- 
plex and MHC class II antigens. J. Exp. Med. 169:1295. 
21.  Gascan, H.,J.-E Gauchat, M.-G. Roncarolo, H. Yssel, H. Spits, 
and J.E. de Vries. 1991. Human B cell clones can be induced 
to proliferate and to switch to IgE and IgG4 synthesis by in- 
terleukin 4 and a signal  provided by activated CD4 + T  cell 
clones. J. Exp. Med. 173:747. 
22.  Bartlett, W.C., and R.J. Noelle. T cell-dependent B-cell acti- 
vation. 1991. In T-Cell Dependent and Independent B-Cell Ac- 
tivation  E.C.  Snow,  editor.  CRC  Press,  Boca Raton,  FL. 
111-138. 
23.  Rousset, F., E. Garcia,  and J. Banchereau. 1991. Cytokine- 
induced  proliferation  and  immunoglobulin  production  of 
human B lymphocytes triggered through their CD40 antigen. 
J. Exp. Med. 173:705. 
24.  Banchereau, J.  1990.  Human interleukin 4 and its receptor. 
In Hematopoietic Growth Factors in Clinical Applications.  R. 
Mertelsmann and F. Herrmann, editors. Marcel Dekker, Inc., 
New York.  433-469. 
25.  Rousset, F., E. Garcia,  T. Defiance, C. P~ronne, N. Vezzio, 
D.-H. Hsu, R. Kastelein,  K.W.  Moore, and J. Banchereau. 
1992. Interleukin 10 is a potent growth and differentiation factor 
for activated human B lymphocytes. Proc Natl. Acad. Sci. USA. 
89:1890. 
26.  Defiance, T., B. Vanbervliet, J.-P. Aubry, and J. Banchereau. 
1988.  Interleukin  4  inhibits  the  proliferation but  not  the 
differentiation of activated human B cells in response to inter- 
leukin 2. J. Exp. Med. 168:1321. 
27.  Karray,  S.,  T.  Defiance, H.  Merle-B~ral,  J.  Banchereau, P. 
Debt6, and P. Galanaud. 1988. Interleukin 4 counteracts the 
interleukin 2-induced proliferation of monoclonal B cells. J. 
Exp. Med. 168:85. 
28.  Holder, M., Y.-J. Liu, T. Defrance, L. Flores-tkomo, I.C.M. 
MacLennan, andJ. Gordon. 1991. Growth factor requirements 
for the stimulation of germinal center B cells: evidence for an 
IL-2-dependent pathway of development. Int. Immunol. 3:1243. 
29.  Miyajima,  A., T. Kitamura, N.  Harada, T. Yokota,  and K. 
Arai. 1992. Cytokine receptors and signal transduction. Annu. 
Rev. Immunol. 10:295. 
30.  Rigley, K., S.M.  Thurstan, and R. Callard.  1991. Indepen- 
dent regulation of interleukin 4 (IL4)-induced expression  of 
human B cell surface CD23 and IgM: functional evidence for 
two IL-4 receptors.  Int. Immunol. 3:197. 
31.  Fanslow, W.C., M.K. Spriggs, C.T. Ranch, K.N. Clifford, B.M. 
Macduff,  S.F. Ziegler,  K.A.  Schooley,  K.M.  Mohler,  C.J. 
March, and R.J. Armitage. 1993. Identification of a distinct 
low affinity receptor for human interleukin-4 on pre-B cells. 
Blood. 81:2998. 
32.  Kuhn, R., K. Rajewsky, and W. Muller. 1991. Generation and 
analysis of interleukin-4 deficient mice. Science (Wash. DC). 
254:707. 
33.  Kopf, M., G. Le Gros, M. Bachmann, M.C. Lamers, H. Blueth- 
mann, and G. Kohler. 1993. Disruption of the murine IL-4 
gene blocks TH-2 cytokine responses. Nature (Lond.). 362:245. 
34.  Zhang, X., B. Polla,  C.  Hauser, and R.H.  Zubler.  1992.  T 
cells from atopic individuals produce IgE-inducing activity in- 
completely blocked by anti-interleukin-4 antibody. Eur.J. Im- 
munol. 22:829. 
143  Defrance  et al. 